A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatment (APOLLO-LOPD)

Brief description of study

Primary Objective:

To evaluate the effect of one-year Alglucosidase alfa treatment on motor function [Six-minute walk test (6MWT) and lung function predicted Forced vital capacity (FVC)] among Chinese Late Onset Pompe Disease patients above 5 years old.

To evaluate the safety of Myozyme 20mg/kg, IV biweekly in Chinese LOPD patients above 3 years old.

Secondary Objective:

To evaluate the effect of one-year treatment with Alglucosidase alfa on improvement of manual muscle test (MMT), Maximal inspiratory and expiratory pressure (MIP and MEP)], Quick Motor Function Test scores, and health-related quality of life (SF-12) among LOPD patients over 5 years old.

Detailed description of study

Study duration per participants is approximatively 56 weeks including a 52-week treatment period.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pompe's Disease
  • Age: 3 Years
  • Gender: Male or Female

Inclusion criteria :

  • Patients (or and patient's legal guardian) must provide written informed consent prior to any study-related procedures
  • The patient must be ≥ 3 years of age at the time of enrollment.
    1. For patient ≥ 3-year and < 5-year old: must be able to walk 10 meters or climb 4-step stairs independently.
    2. For patients ≥5-year old
    3. Must be able to ambulate 40 meters in 6 minutes without assistance ii. Must be able to successfully perform repeated forced vital capacity (VC) measurements in upright position of ≥ 30% predicted and ≤85% predicted.
  • The patient has confirmed Pompe's Disease with at least 2 of the following condition,
    1. GAA enzyme deficiency from any tissue source.
    2. 2 confirmed GAA gene mutations.
    3. muscle pathology meet the diagnosis of Pompe disease.
  • The patient (and patient's legal guardian if patient is legally minor as defined by

    local regulation) must have the ability to comply with the clinical protocol.

  • The patient, if female and of childbearing potential, must have a negative pregnancy test (beta-human chorionic gonadotropin) at baseline.

Exclusion criteria:

  • Use of invasive ventilatory support (Invasive ventilation is defined as any form of ventilatory support applied with the use of an endotracheal tube.)
  • Use of non-invasive ventilatory support while awake and in an upright position. (Non-invasive ventilation is defined as any form of ventilatory support applied without the use of an endotracheal tube.)
  • Previously treated with Enzyme Replacement Treatment.
  • A Female patient of childbearing potential with a positive pregnancy test.
  • Wheelchair dependent.
  • The patient has a major congenital anomaly.
  • The patient has a medical condition, serious intercurrent illness, or other extenuating circumstance, in the opinion of the Investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities.
  • The patients with ≥5-year old are unable to ambulate 40 meters without assistance or unable to successfully perform repeated FVC of >30% and <85% predicted (upright).
        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.

Updated on 27 Oct 2022 . Study ID: NCT04676373

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site